Abbott Hepatitis C Therapy Works After Other Drugs Fail
This article is for subscribers only.
Abbott Laboratories’ experimental hepatitis C treatment cured almost half of patients who couldn’t eliminate the virus with therapies now on the market, according to a study that boosted the company’s shares.
The Abbott-funded research found that eight of 17 patients who didn’t improve on standard-of-care treatments had no detectible virus levels after three months on the therapy, which combines two products, the Abbott Park, Illinois-based company said in a statement. Abbott rose less than 1 percent to $61.46 at 4 p.m. New York time, the highest closing price since at least 1980, according data compiled by Bloomberg.